Results of 3-month additional treatment with pioglitazone in the study patients divided into two subgroups
| Variables | Nonresponders (n = 30) | Responders (n = 40) | ||||
|---|---|---|---|---|---|---|
| Baseline | 3 months | Baseline | 3 months | |||
| Sex (male/female) | 12/18 | 20/20 | ||||
| Age (years) | 60.4 ± 2.1 | 61.8 ± 1.6 | ||||
| BMI (kg/m2) | 22.7 ± 0.6 | 23.0 ± 0.6† | 23.9 ± 0.5 | 23.9 ± 0.5 | ||
| SBP (mmHg) | 144 ± 4 | 143 ± 3 | 144 ± 3 | 146 ± 3 | ||
| DBP (mmHg) | 80 ± 2 | 80 ± 2 | 82 ± 2 | 83 ± 3 | ||
| FPG (mmol/l) | 9.4 ± 0.5 | 8.9 ± 0.4 | 9.7 ± 0.5 | 7.3 ± 0.4†‡ | ||
| HbA1c (%) | 7.8 ± 0.2 | 7.7 ± 0.2 | 8.3 ± 0.1‡ | 6.8 ± 0.1†‡ | ||
| IRI (pmol/l) | 49.7 ± 4.96 | 46.8 ± 4.75 | 63.3 ± 5.76 | 55.5 ± 8.42 | ||
| HOMA-IR | 2.96 ± 0.38 | 2.62 ± 0.31* | 3.65 ± 0.42 | 1.97 ± 0.16†‡ | ||
| Total cholesterol (mmol/l) | 5.40 ± 0.12 | 5.42 ± 0.11 | 5.51 ± 0.15 | 5.27 ± 0.16* | ||
| LDL cholesterol (mmol/l) | 3.32 ± 0.09 | 3.27 ± 0.09 | 3.30 ± 0.11 | 3.09 ± 0.12* | ||
| HDL cholesterol (mmol/l) | 1.37 ± 0.08 | 1.43 ± 0.08 | 1.50 ± 0.07 | 1.51 ± 0.07 | ||
| Triglycerides (mmol/l) | 1.54 ± 0.06 | 1.56 ± 0.05 | 1.57 ± 0.05 | 1.46 ± 0.06* | ||
| Adiponectin (μg/ml) | 5.98 ± 0.52 | 7.48 ± 0.71† | 6.07 ± 0.46 | 8.08 ± 0.73† | ||
| Leptin (ng/ml) | 6.16 ± 0.79 | 6.21 ± 0.77 | 6.79 ± 0.66 | 6.95 ± 0.56 | ||